Editas wins approval to launch EDIT-401 Strive trial
Editas Medicine (EDIT) received approval in Australia to start a Phase 1/2 trial of EDIT-401, a gene editing therapy for familial hypercholesterolemia. The trial will begin in Australia and New Zealand, with early safety data expected in Q1 2027. Analysts have a $5.00 price target and a Buy rating, while TipRanks' AI Analyst rates it Neutral due to financial performance and technical factors.
How this was made
The 30-second read
Why it matters
Australia approval to start the Strive Phase 1/2 trial is a tangible regulatory milestone that can improve perceived execution risk and support forward pipeline valuation, while New Zealand review remains a gating item for full site rollout.
Market read
Traders may reassess EDIT’s probability-weighted pipeline timeline after a jurisdiction-specific approval, but the next tradable datapoint is the first safety/tolerability readout targeted for Q1 2027.
What to watch
The article does not provide dosing details, comparator strategy beyond placebo expansion, or any interim efficacy expectations, so near-term valuation impact may be limited until early safety data are reported.
Background
Editas Medicine is a clinical-stage biotech developing CRISPR-based in vivo gene editing therapies; EDIT-401 targets upregulation of the LDL receptor gene to lower LDL-C and other atherogenic lipoproteins.
Ticker impact
Editas Medicine received Australian approval to start the Phase 1/2 Strive trial of EDIT-401 for heterozygous familial hypercholesterolemia, with New Zealand review pending.
Likely upward bias as investors price in reduced regulatory friction and earlier safety readouts.
The article’s newest, attributable fact is approval to begin the trial, plus a stated schedule for early safety/tolerability readouts in Q1 2027 and dose-finding topline later in 2027.
Market effects
Adds incremental momentum to the in vivo gene editing and cardiovascular/lipid-disorder trial pipeline narrative.
Highlights Australia as a key jurisdiction for trial execution, with New Zealand submission still under review.
If Strive progresses, it can strengthen global investor confidence in gene editing approaches for LDL-C and atherogenic lipoproteins.
Counterpoint
Trial approval does not guarantee clinical success; investors may fade the news if safety signals or LDL-C efficacy do not materialize in later readouts.
Key entities
- companyEditas Medicine
Sponsor of the EDIT-401 Strive Phase 1/2 clinical trial; received approval in Australia to begin dosing.
- programEDIT-401
Experimental in vivo gene editing therapy intended to upregulate the LDL receptor gene to lower LDL-C, Lp(a), and ApoB.
- clinical_trialStrive trial
Phase 1/2 study in heterozygous familial hypercholesterolemia with an open-label single ascending dose followed by randomized placebo-controlled expansion.
